LONDON – Vasopharm GmbH announced that the Phase IIa trial of its nitric oxide inhibitor VAS203 not only cleared all the safety, tolerability and pharmacokinetic hurdles, but also led to "substantially improved" neurological recovery at six months in traumatic brain injury (TBI) patients. Read More
LONDON – An antibiotic compound originally described in 1953, but never developed, could hold the key to new treatments for multidrug-resistant strains of tuberculosis. Read More
LONDON – Virttu Biologics Ltd. hired biotech veteran Steven Powell as CEO, with a brief to reshape strategy and turbo-charge efforts to commercialize oncolytic virus Seprehvir, a broad-spectrum product that has yet to reach the advanced stages of clinical development despite having been tested in more than 75 patients, in a number of solid tumors. Read More
With positive overall survival data from a Phase II trial in hand, 4SC AG aims to move its pan-histone deacetylase inhibitor (HDAC) resminostat into a pivotal Phase III trial in second-line hepatocellular carcinoma (HCC) in the first half of next year. Read More
The €80 million (US$104.9 million) investment by dievini Hopp BioTech Holding GmbH & Co. KG in Tuebingen, Germany-based CureVac GmbH is not only its single biggest bet to date, but also a clear point of differentiation between itself and most other private investors in European biotechnology. (See story this issue.) Read More
Taking advantage of a summer stock climb on the back of its allogeneic cell therapy pipeline, Pluristem Therapeutics Inc. is nearly doubling its cash position with a $32 million public offering. Read More
• Biotie Therapies Corp., of Turku, Finland, registered 65.1 million new shares in a directed issue of shares to H. Lundbeck A/S, and to institutional and strategic investors. Read More
